01 原文阅读 
738words(不包括标题)
本文选自经济学人20211016Business版块
Health technology
Girls uninterrupted
Femtech firms are enjoying an investment boom. About time
A hormone called relaxin helps loosen up pregnant women’s hips. Without it, the pain of delivery would be unbearable. Its job done, however, relaxin lingers in female bodies for up to a year, when softer ligaments make new mothers more prone to injury, as Jessica Ennis-Hill, an Olympic champion heptathlete, discovered in training after giving birth in 2014. Five years later Dame Jessica started Jennis, a fitness app to help other women perform safe post-natal workouts. It now lets users optimise workouts for the different phases of their menstrual cycles, and has just concluded a successful funding round.
Dame Jessica’s startup is part of a wave of “femtech” firms coming up with ways for women to overcome health problems specific to their sex. The market could more than double from $22.5bn last year to more than $65bn by 2027, reckons Global Market Insights, a research firm. Having ignored it for years—in 2020 femtech received only 3% of all health-tech funding, and a modest $14bn has been invested in it globally to date—venture capitalists are at last waking up to the opportunity. So far this year they have invested nearly $1.2bn in the industry, nearly half as much again as the annual record in 2019 (see chart).
Last year Bayer, a big German drugmaker, paid $425m to buy KaNDy, a British developer of a non-hormonal treatment for menopause symptoms, and Bill Gates, Microsoft’s billionaire co-founder, backed BIOMILQ, a startup that has produced cell-cultured human breast milk and aims to bring both parents closer to their newborns. In August Maven Clinic, an American startup which began as a femtech but has expanded to other areas of health, raised $110m and achieved “unicorn” status, with a valuation of more than $1bn. In September Elvie, another British firm, raised $97m from venture-capital firms.
Unlike heath tech aimed at men, which often focuses on erectile dysfunction, a condition that afflicts perhaps one in ten potential users, femtech offers products like period trackers, which could be of value to virtually all of the world’s 4bn women at some point in their lives. Moreover, women are 75% likelier than men to adopt digital tools for health care. That makes for a huge potential market.
A big reason femtech has been slow to grow has to do with the underlying medical science. For conditions that affect all humans, men are more commonly studied, largely owing to misplaced worries that women’s hormonal fluctuations can confound results (male mice are favoured for the same reason). In the few more inclusive studies, results are seldom disaggregated by sex, obscuring how diseases—and the drugs used to treat them—affect women differently. “We have been operating as if women are just smaller versions of men,” observes Alisa Vitti, a hormone expert whose work on the 29-day “infradian” body clock, which affects everything from metabolism to sensitivity to pain and is a uniquely female phenomenon, underpins many period trackers.
As a result, plenty of woman-specific health issues have, despite their ubiquity, been routinely neglected. Femtechs help fill this research gap. Noting that eight in ten women suffer from premenstrual pain but no treatments have been specifically designed to allay it, founders of Daye, a British startup, designed a tampon laced with cannabidiol, after observing that the vaginal canal has more cannabinoid receptors than any other part of the female body.
Hertility Health, also of Britain, offers non-invasive tests which can help diagnose nine common gynaecological conditions. Elvie’s silent wearable breast pump is a best-seller in America and Britain; its app-controlled pelvic-floor trainer reduces the chances of the typical intervention, whereby surgeons insert “a fishing net and lift up your pelvic organs because they are falling out of your vagina”, says Tania Boler, the firm’s founder.
Labour pains
That is welcome progress. But too many femtechs face an uphill struggle. Helen O’Neill, who runs Hertility Health, calls the $5.7m funding round her firm closed in June a “soul-destroying” process. “It was predominantly grey-haired men saying they are not sure there is a market for this,” she says. Never mind that all women with a reproductive system require gynaecological help at some point. 
本篇中文翻译
请扫码关注翻译专用新号
当天17:30发布同篇译文
《一天一篇经济学人姊妹号》
02 我们招人啦
人的一生,会遇到形形色色的人。大多数与你短暂相交,然后渐行渐远。只有极少数能与你走在同一轨道。我们寻找的是这个极少数同频同轨的小伙伴。
请大家一定仔细阅读下推文我们招人啦!满足条件再加小编,设置严格的条件,只是希望能保证译文质量,对34w+读者负责!
#梦想始于行动
It all started with just one small step.
what's one small step yhat you could take today.
03 免费外刊分享群 
后台总是有小伙伴私信小编要外刊,小编虽然已经发过多次推文,例如获取经济学人的N种方法如何在官网半价订阅经济学人,讲过了这么多方法,但还是有辣么多小伙伴不会或者懒得弄。于是小编这次再建了群,会每周在群里分享外刊,有兴趣的小伙伴扫码进群(已经加入公众号其他群的小伙伴请不要重复加群),谢谢。如果群又满了,请转发这篇文章到朋友圈,私信小编微信396196827即可加入进群。进群广告者一律踢,不接受任何解释,谢谢理解。
扫以下二维码进群:
1.每天早上群里分享The world in brief
为什么要读the world in brief?引用翻译组 裸考过一笔经验贴中写的一段话:每天精读经济学人EspressoEspresso相当于经济学人的微缩版,每周六天,每天五篇,给阅读经济学人提供了必要的背景知识。每天看有连贯性,如同看一部连续剧,而世界就是这个大舞台。
2.每周群里分享的外刊如下,如图所示
特别注意:
如果大家想获取
2001-2021年所有的经济学人PDF,请按照以下操作:
1. 转发本文到朋友圈全部可见或 100人以上英语微信群(一天一篇经济学人社群除外)
2. 
转发后两小时截图私信小编
396196827,小编会在晚上通过(白天在工地),通过后发给您,谢谢理解。

---END---
继续阅读
阅读原文